Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint
Study: Rencarex Treatment Efficacy Increases With CAIX Antigen Density in Tumor Tissue
DSMB Recommends Discontinuing Phase III Perifosine Combination Trial
51% Control Rate Achieved In Phase II Trial of Elderly Patients
Study: Partial Kidney Removal Leads to Greater Survival
Phase IIb Trial of CRLX101 Fails Overall Survival Endpoint
AIDS Cachexia Drug Stabilizes Body Weight, Muscle Mass
Two Children Achieve Remission With CD19 Immunotherapy
Adjuvant Chemotherapy Unneeded In Children with Low-Risk Disease
Study: Oncotype DX Score Can Predict Local Recurrence
BRAF Mutation Testing Classifies Indeterminate FNA Samples
NCI CTEP Approved Trials For the Month of March
FDA Approves Lymphoseek For Imaging Lymph Nodes
Trending Stories
- Trump executive order to “Make America Healthy Again” cites questionable data from Wuhan
White House cites paper in pay-to-play journal claiming that U.S. has highest age-standardized incidence rate of cancer - FDA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers
- Fired NCI employee says Trump’s purge was baseless yet punitive
“I feel like I’ve been erased” - As cancer research is threatened, we must engage in political advocacy
- “The Agency finds you are not fit…”
HHS notifications of firing add insult to injury - Pushing for tax cuts, Trump threatens the federal workforce, Medicaid, and cancer research
